HMGCR dimer binds statins

Stable Identifier
R-HSA-9705584
Type
Reaction [binding]
Species
Homo sapiens
Compartment
ReviewStatus
5/5
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Dimeric 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR dimer) is the key enzyme in the cholesterol biosynthetic pathway and catalyzes the committed step of the reduction of beta-hydroxy-3-methylglutaryl CoA (bHMG-CoA) to mevalonate. HMGCR is regarded as one of the most important drug targets in the treatment of hypercholesterolemia. HMGCR inhibitors, commonly referred to as statins, are among the most widely prescribed drugs in the world. Statins work by their similarity to the substrate (bHMG-CoA), leading to competition towards the HMG binding site on the enzyme between substrate and statins (Istvan & Deisenhofer 2001). As statins also block the access of the substrate to the binding site, the affinity of HMGCR for statins is slightly higher than its affinity for the substrate (Istvan 2002, Carbonell & Ernesto Freire 2005, Gesto et al. 2020). Statins can be divided in two types, according to their origin. Type I statins e.g. lovastatin, pravastatin and simvastatin, are natural fungal products and Type II statins e.g. atorvastatin, rosuvastatin and fluvastatin, are fully synthetic.
Literature References
PubMed ID Title Journal Year
12486413 Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase

Istvan, ES

Am Heart J 2002
16128575 Binding thermodynamics of statins to HMG-CoA reductase

Freire, E, Carbonell, T

Biochemistry 2005
11349148 Structural mechanism for statin inhibition of HMG-CoA reductase

Istvan, ES, Deisenhofer, J

Science 2001
Participants
Participates
Orthologous Events
Authored
Reviewed
Created
Cite Us!